Customer & Industry Requirements
Software categories requiring risk-scaled validation
GMP inspection findings linked to computerized system deficiencies
FDA finalized Computer Software Assurance guidance
Regulation Overview
GAMP 5 is ISPE's globally recognized guideline for validating computerized systems in pharmaceutical and regulated manufacturing environments. For supply chain and quality teams, the core obligation is ensuring every automated system affecting product quality, patient safety, or data integrity is validated proportionally to its risk—with full lifecycle documentation from initial qualification through retirement.
The Second Edition (2022) expanded coverage to cloud computing, AI/ML, agile development, and supplier ecosystem management. FDA's finalized Computer Software Assurance guidance (September 2025) formally endorses the risk-based validation approach GAMP 5 has advocated for years. The EU's draft revision of Annex 11, expected to finalize mid-2026, aligns directly with GAMP 5 principles.
GAMP 5 compliance requires category-specific validation documentation—user requirements, risk assessments, IQ/OQ/PQ protocols, and audit trails—from every system supplier and integrator.
Pharmaceutical and biotech manufacturers operating computerized systems under GMP
Medical device manufacturers subject to FDA 21 CFR Part 820 and ISO 13485
Contract manufacturers (CMOs/CDMOs) processing GxP data on behalf of sponsors
Equipment and software suppliers providing systems used in GMP environments
Laboratories using LIMS, chromatography data systems, or ELNs under GLP/GMP
Companies deploying cloud, SaaS, or AI-based tools in production or quality operations
Key Thresholds
A mid-size pharmaceutical manufacturer operates 40+ computerized systems across production, quality, and laboratory functions. The Second Edition expanded scope to include cloud platforms and AI tools—but validation packages for half the systems are based on pre-2022 standards. Your team spends months remediating documentation gaps, and every new SaaS deployment adds another system to the backlog.
A new LIMS vendor sends a 200-page validation package. Your QA team needs to verify it covers GAMP Category 4 requirements—configuration specifications, test evidence, and audit trail capabilities. The vendor's documentation is incomplete. You request supplements. Three weeks pass. Meanwhile, the system is live in a clinical environment with no approved validation summary.
GAMP 5 applies validation depth based on software category—but a single spreadsheet used for GMP batch calculations can shift from Category 1 infrastructure to Category 5 custom software if it contains macros. Without systematic classification of every system in your portfolio, audit findings accumulate. Inspectors cite uncontrolled spreadsheets as one of the top data integrity violations.
Every GxP system requires ALCOA+ compliant audit trails with periodic review. Complex manufacturing environments with dozens of systems generate thousands of audit trail entries monthly. Manual review is unsustainable—yet 30–35% of GMP inspection findings still originate from weak data integrity and incomplete lifecycle governance in computerized environments.
Certivo In Action
Certivo in Action — GAMP 5 Workflow
Features Tabs
Pharmaceuticals & Biotech
Your Pain Point
Dozens of GxP systems across manufacturing, QC, and clinical; validation backlog growing with AI/cloud adoption
Medical Devices & Equipment
Your Pain Point
FDA QMSR transition requires ISO 13485 alignment; CSA guidance changes validation expectations for production software
Chemical Manufacturing
Your Pain Point
Process control systems, LIMS, and batch record software require lifecycle validation under multiple global GMP frameworks
Electronics Manufacturing
Your Pain Point
Cleanroom automation, SPC systems, and MES platforms require GAMP 5 validation when serving pharma OEMs
Automotive Manufacturing
Your Pain Point
IATF 16949 quality systems intersect with pharma supply when providing components for medical or drug delivery devices
Industrial Machinery & Heavy Equipment
Your Pain Point
Equipment suppliers to pharma must provide GAMP-compliant validation evidence for Category 3/4 systems
From Manual Compilation to Exception Management
CORA extracts validation evidence automatically using AI-native compliance automation. Your team focuses on risk-justified exceptions—not compiling IQ/OQ/PQ binders from scattered supplier documentation.
Inspection Response Acceleration
Generate complete, audit-ready GAMP 5 validation summary packages in hours—not the 4–6 weeks of manual compilation that leaves your team exposed during unannounced inspections.
Proactive GAMP 5 Compliance Monitoring
When FDA, EMA, or PIC/S updates validation expectations, Certivo reassesses your system portfolio instantly through regulatory intelligence and horizon scanning. Know which systems require revalidation before inspectors ask.
Frequently Asked Questions
What systems and companies are subject to GAMP 5 compliance requirements?
Any organization operating computerized systems in a GxP-regulated environment must validate those systems. This includes pharmaceutical and biotech manufacturers, medical device companies, contract manufacturers, and laboratories using LIMS, MES, ERP, or QMS platforms in production or quality operations. Equipment and software suppliers to these organizations must also provide GAMP 5-aligned validation documentation. CORA automates the collection and validation of this documentation across your entire supplier base.
What are the consequences of failing to meet GAMP 5 validation standards?
GAMP 5 itself is industry guidance, not law—but the regulations it supports (FDA 21 CFR Part 820, EU GMP Annex 11, 21 CFR Part 11) carry enforcement authority. FDA warning letters, EU inspection findings, import alerts, and product recalls frequently cite computerized system validation deficiencies. Approximately 30–35% of system-related GMP findings originate from data integrity and lifecycle governance failures in computerized environments.
How does Certivo track updates to GAMP 5 and related regulatory frameworks?
Certivo maintains continuous sync with FDA, EMA, PIC/S, and ISPE regulatory updates through built-in regulatory intelligence and horizon scanning capabilities. When new guidance is issued—such as the FDA CSA update in February 2026 or the expected EU Annex 11 finalization mid-2026—CORA reassesses your system portfolio and alerts you to affected systems, triggering appropriate revalidation and documentation workflows automatically.
What documentation formats does Certivo accept from system suppliers?
Certivo accepts any format through AI document parsing and certificate validation: PDF validation packages, Excel-based IQ/OQ/PQ matrices, vendor audit reports, configuration specification documents, and freeform responses. CORA extracts validation evidence regardless of format or language, eliminating the need to standardize supplier inputs across your multi-tier supply chain.
Does Certivo support both FDA and EU validation requirements alongside GAMP 5?
Yes. Certivo validates against FDA 21 CFR Part 11, the FDA CSA framework, EU GMP Annex 11 (current and draft revision), ISO 13485, and ICH Q9 simultaneously—all from a single supplier submission. This centralized supplier self-service portal approach eliminates duplicate qualification campaigns across frameworks and ensures continuous compliance monitoring and audit readiness regardless of which regulatory body conducts the inspection.